Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.61 |
| ▸ | ACACA | Q13085 | 14/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130151 | 0.90 | ACACB (0.59) | ACACBACACA | |
| SCHEMBL30130144 | 0.87 | ACACB (0.48) | ACACBACACAGAA | |
| SCHEMBL14945261 | 0.86 | ACACB (0.54) | ACACBACACAGAA | |
| SCHEMBL14945319 | 0.85 | ACACB (0.61) | ACACBACACA | |
| SCHEMBL16370031 | 0.85 | ACACB (0.48) | ACACBACACAGAA | |
| SCHEMBL21980390 | 0.80 | ACACB (0.68) | ACACBACACA | |
| SCHEMBL14945494 | 0.79 | ACACB (0.54) | ACACBACACA | |
| SCHEMBL14950652 | 0.78 | ACACB (0.56) | ACACBACACA | |
| SCHEMBL14945260 | 0.78 | ACACB (0.59) | ACACBACACA | |
| SCHEMBL14935982 | 0.78 | ACACB (0.59) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273132-A2 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | Gilead Sciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3589636-B1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20210024537-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10745412-B2 | Processes for preparing ACC inhibitors and solid forms thereof | GILEAD SCIENCES, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200199147-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024537-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885GAA 84/4885 |
| US-10745412-B2 | Processes for preparing ACC inhibitors and solid forms thereof | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885GAA 84/4885 |
| US-20200199147-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | ACACA, ACACB, ACAT2 | ACACB 2/4885ACACA 1/4885GAA 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.